Antagomirs Targeting MicroRNA-134 Increase Hippocampal Pyramidal Neuron Spine Volume in Vivo and Protect Against Pilocarpine-induced Status Epilepticus
Overview
Authors
Affiliations
Emerging data support roles for microRNA (miRNA) in the pathogenesis of various neurologic disorders including epilepsy. MicroRNA-134 (miR-134) is enriched in dendrites of hippocampal neurons, where it negatively regulates spine volume. Recent work identified upregulation of miR-134 in experimental and human epilepsy. Targeting miR-134 in vivo using antagomirs had potent anticonvulsant effects against kainic acid-induced seizures and was associated with a reduction in dendritic spine number. In the present study, we measured dendritic spine volume in mice injected with miR-134-targeting antagomirs and tested effects of the antagomirs on status epilepticus triggered by the cholinergic agonist pilocarpine. Morphometric analysis of over 6,400 dendritic spines in Lucifer yellow-injected CA3 pyramidal neurons revealed increased spine volume in mice given antagomirs compared to controls that received a scrambled sequence. Treatment of mice with miR-134 antagomirs did not alter performance in a behavioral test (novel object location). Status epilepticus induced by pilocarpine was associated with upregulation of miR-134 within the hippocampus of mice. Pretreatment of mice with miR-134 antagomirs reduced the proportion of animals that developed status epilepticus following pilocarpine and increased animal survival. In antagomir-treated mice that did develop status epilepticus, seizure onset was delayed and total seizure power was reduced. These studies provide in vivo evidence that miR-134 regulates spine volume in the hippocampus and validation of the seizure-suppressive effects of miR-134 antagomirs in a model with a different triggering mechanism, indicating broad conservation of anticonvulsant effects.
Guerra Leal B, Carvalho C, Santos C, Samoes R, Martins-Ferreira R, Teixeira C Front Mol Neurosci. 2025; 17:1512860.
PMID: 39744540 PMC: 11688299. DOI: 10.3389/fnmol.2024.1512860.
Parkins E, Gross C J Neurosci. 2024; 44(32).
PMID: 39111834 PMC: 11308354. DOI: 10.1523/JNEUROSCI.0365-24.2024.
Jiao D, Xu L, Gu Z, Yan H, Shen D, Gu X Neural Regen Res. 2024; 20(4):917-935.
PMID: 38989927 PMC: 11438347. DOI: 10.4103/NRR.NRR-D-23-01444.
Darbinian N, Hampe M, Martirosyan D, Bajwa A, Darbinyan A, Merabova N Int J Mol Sci. 2024; 25(11).
PMID: 38892014 PMC: 11172088. DOI: 10.3390/ijms25115826.
Tumor Suppressor MicroRNAs in Clinical and Preclinical Trials for Neurological Disorders.
Lui A, Do T, Alzayat O, Yu N, Phyu S, Santuya H Pharmaceuticals (Basel). 2024; 17(4).
PMID: 38675388 PMC: 11054060. DOI: 10.3390/ph17040426.